Dr. Lakshmi Nayak, director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute, explained in an interview with CURE that the Food and Drug Administration (FDA) removal of primary central ...
Recent regulatory actions from the FDA, including new drug application (NDA) acceptances and labeling updates, introduce new clinical considerations for oncology nurses and advanced practice providers ...
Abstract: Fully actuated system (FAS) approach was proposed in 2020 and 2021 as a general framework for control system analysis and design based on a newly discovered general type of fully actuated ...
Metabolomics-Derived Pathway Scores Outperform Inflammatory Protein Markers-Delivering Risk Prediction Where Proteomics Falls Short ...
H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma ...
Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...
The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...
FDA lifts Yescarta limits for relapsed primary CNS lymphoma, expanding CAR T access with phase 1 safety data—what to know about neuro risks. The FDA has approved a label update for axicabtagene ...
Abstract: The VLSI industry for semiconductors has undergone a transformation thanks to System-on-Chip technology. Recently, semiconductor hobbyists have been using a revolutionary approach, primarily ...
Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results